Sidley Healthcare Investment Conference 2023
2023-09-12 11:30 - 18:30 (Europe/London) | The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, United Kingdom
With deal and investment activity remaining critical for the success of the life sciences and healthcare industry, Sidley is bringing together senior pharma, biotech, healthcare, private equity, and venture capital leads to provide their insights on key topics, trends, and opportunities.
RSVP Here
Join Sidley and industry leaders from across the globe for this in-person, one-day event in London, with the option to stream and network virtually from outside the UK.
We look forward to incisive content, robust discussion, and valuable networking during a day looking at the continued combination of innovation and capital driving positive patient outcomes and investment returns.
View confirmed speakers.
View agenda.

Please note, due to space limitation for this event, registrations will be reviewed and confirmed by email in due course. We strongly encourage in-person attendance and remote participation will be available to those based outside of the UK.
The health of our clients, colleagues, and guests is important to us. If you are experiencing cold or flu-like symptoms please stay home and get better. If you are recovering from COVID-19 or have been recently exposed, please follow applicable guidelines.
For more information or questions, please contact lnevents@sidley.com.

Boston Life Sciences Roundtable
2024-05-01 | MassBio Hub, 700 Technology Square, Cambridge, MA 02139
Join Sidley at our annual Boston Life Sciences Roundtable for an afternoon of engaging discussion addressing cutting-edge trends and hot topics.

1:30 p.m. Registration | 2:00 p.m. Program | 5:00 p.m. Reception
For more information, contact bosevents@sidley.com.
FEATURED PANEL TOPICS

I Used To Practice Law: A Conversation with Life Sciences Leaders
A rare few life sciences leaders have served in both chief legal and chief business officer roles during the course of their careers. Join our discussion of making the transition

Anna Barry, Venture Partner, Deerfield Management
Jerald Korn, Chief Executive Officer, Ropirio Therapeutics, Inc.
Asher Rubin, Partner, Global Co-leader, Technology and Life Sciences Transactions
Becky Wood, Partner, Global Co-leader, Food, Drug and Medical Device and former FDA Chief Counsel

Strategies for Success: Navigating Current Healthcare and FDA Trends for Life Sciences Companies
The session will cover hot topics and regulatory developments from both an FDA and healthcare perspective.

Scott Kaplan, Deputy General Counsel, Baxter International Inc.
Peter Smith, Head of Legal, argenx US, Inc.
Donielle McCutcheon, Partner, Healthcare
Jim Johnson, Partner, Food, Drug and Medical Device

Life Sciences Transactions: Updates and Perspectives on the Market
From green shoots and increased deal activity to supply chain disruptions and Congressional investigations, this panel will explore important updates affecting the environment for life sciences transactions.

Andy Meyerson, Managing Director, Locust Walk

Jason Russell, Managing Director, Global Head of Biotechnology, Morgan Stanley
Michael Borden, Partner, Leader, Government Strategies
Alison Lehner, Partner, Emerging Companies and Venture Capital
Adriana Tibbitts, Partner, Technology and Life Sciences Transactions

ICCA 2024 Hong Kong Sidley Breakfast Seminar
2024-05-07 08:00 - 09:30 (America/Chicago) | The Clipper, The American Club, Floors 48-49, Two Exchange Square, Central, Hong Kong
Join us for an engaging and informative panel discussion on life sciences disputes as part of ICCA 2024 Hong Kong. Our panel comprising Sidley disputes and life sciences specialists as well as inhouse counsel will explore (i) general trends in life sciences transactions, (ii) the complexities and unique challenges involved in life sciences disputes with a focus on IP and cross-border issues, (iii) strategies on how to avoid and manage potential disputes in life sciences transactions, and (iv) case studies and practical insights.
RSVP Here

8:00 a.m. HKT: Registration
8:30 – 9:30 a.m. HKT: Panel discussion
Our international panel of specialists will comprise partners from Sidley’s Global Arbitration, Trade and Advocacy and Global Life Sciences practices, as well as representatives from the life sciences industry.

FDA’s New Wave of Promotion Enforcement: What You Need to Know Now
2024-05-14 13:00 - 14:00 (America/New_York)
After several years of relatively little enforcement, FDA has recently been flexing its muscles in the promotion area. The Office of Prescription Drug Promotion (OPDP) in particular has issued several notable warning and untitled letters in the past year, representing an increased volume in enforcement and increased scrutiny of efficacy claims. This includes more rigorous assessment of information “consistent with” FDA-required labeling (CFL) and enforcement of new expectations for presentation of quantitative efficacy information. Tune in to this overview session for an efficient rundown of what this means for drug, biological product, and device manufacturers in terms of key watchouts and practical approaches to risk mitigation.
RSVP here.

1:00 p.m. – 2:00 p.m. ET
CLE credit will be offered for this webinar.
Sidley Austin LLP is an accredited MCLE provider in IL, NY, and CA. Credit is available for CT, NJ, TX, and VA upon request.

Swiss MedTech 2024: Harnessing Market Dynamics for Profitability
2024-09-04 | Farelhaus, Oberer Quai 12, 2503 Biel, Switzerland, Switzerland
Join Sidley, ISS AG, and Swiss Medtech in Biel for an afternoon of practical tips and interactive discussions on current issues, including:

ESG and its development in the EU
Seizing the opportunities of Artificial Intelligence
Health data and clinical trials

2:00 p.m. – 6:30 p.m. CET
Followed by a networking drinks reception
RSVP here.
Industry speakers, regulators, scientific experts, and counsel will share tips and best practices for the challenges and opportunities that lie ahead for Swiss MedTech.
WHO SHOULD ATTEND?
Executives, investors, in-house counsel, and regulatory managers interested in and/or facing regulatory issues in Switzerland.
For more information, please contact Dafne Forni Zervoudaki at +32 2 504 6202 or at dafne.fornizervoudaki@sidley.com.

Data Integrity and Governance Workshop
2024-09-09 - 2024-09-13
Live Oak Workshops, in collaboration with Sidley Austin, are designed to equip you with the knowledge and critical thinking strategies that lead to success in the advancement of your GXP career. As worldwide regulatory expectations in the world of data integrity and data governance change, our workshops prepare you with the skills necessary to interpret regulations, guidance, and regulatory action into simple approaches for managing your everyday GXP responsibilities with the efficiency needed to thrive.
Monday, September 9, 2024 – Tuesday, September 10, 2024 | Ahmedabad, India
Thursday, September 12, 2024 – Friday, September 13, 2024 | Hyderabad, India
Sign up now to join us as we discuss, debate, question, and tackle interesting regulatory case studies in the world of data integrity and data governance.
We are excited to now offer this worship in both Ahmedabad and Hyderabad this October. Click here to see the full two-day agenda.
Instructors include former FDA India Office alums:
Peter Baker, President, Live Oak
Former FDA Investigator
Peter Baker is a GXP consultant focused on improving the quality of medicines by providing training and consulting services to organizations looking to improve the quality of their data integrity assurance strategy. Pete is a former FDA investigator whose Agency leadership included serving as Assistant Country Director (Drugs) in New Delhi, where he performed high risk cGMP inspections of human drug manufacturers throughout India and the surrounding region, conducted a variety of training and development exercises for manufacturers and foreign regulators, performed joint GMP manufacturing inspections with a variety of foreign regulatory bodies, and conducted joint investigations alongside local and regional investigation teams to facilitate harmonized regulatory actions. In 2013, he was recognized as FDA Investigator of the year due to a significant number of FDA regulatory actions taken in India, including product recalls and import bans based on inspections where breaches in data integrity were uncovered which affected a wide variety of products in US distribution.
Jay Jariwala, Senior Director, Regulatory Compliance, Sidley
Former FDA Regulator
For over 13 years, Jay served as an FDA regulator and leader at multiple FDA centers, including CDER, the Center for Devices and Radiological Health (CDRH), and the Office of the Commissioner, applying the agency’s laws, regulations, guidance, and other technical and administrative policies on drugs, medical devices, and combination products to policy development, facility inspections, compliance, enforcement, and approval processes. His FDA leadership experience includes serving as assistant country director (Drugs) and supervisory Consumer Safety officer in the agency’s India Office in New Delhi, where he managed a team of investigators for all facility inspections conducted by the India Office and compliance follow-up. In addition to his responsibilities for resource planning and operational oversight for violative establishment inspection assessments and resulting regulatory actions, Jay trained FDA investigators on current good manufacturing practice (CGMP) requirements — particularly data integrity and quality investigations.
Dan Roberts, Senior Director, Regulatory Compliance, Sidley
Former FDA Investigator
Dan Roberts evaluates and assesses pharmaceutical quality systems and focuses on detecting and remediating data integrity concerns and evaluating compliant automated manufacturing processes and related computerized systems. He provides guidance and assists clients in responding to FDA-483 observations, corresponding with regulatory agencies, and conducting mock FDA facility audits. Dan has over 20 years of government regulatory and pharmaceutical/biopharmaceutical industry experience. He was an FDA investigator for eight years, including two years as the primary point of contact for conducting pharmaceutical inspections at the FDA India office located at the U.S. Embassy in New Delhi. He was also the first lead investigator for the first biosimilar inspection conducted by the FDA in India.
Jim Johnson, Partner, Sidley
Former FDA Associate Chief Counsel
Jim Johnson guides life sciences companies through complex FDA compliance and enforcement matters, including inspections, current good manufacturing practices (GMP) requirements, data integrity responsibilities, product quality issues, pharmacovigilance obligations, and enforcement actions. Jim previously served as Associate Chief Counsel for Enforcement in the FDA’s Office of the Chief Counsel, where he handled GMP enforcement and provided legal counsel on a range of inspectional and compliance issues to agency components, particularly the FDA’s Office of Regulatory Affairs (ORA) and Center for Drug Evaluation and Research’s (CDER) Office of Compliance. Jim uses his extensive agency and private practice experience to assist pharmaceutical and biotechnology companies worldwide, regularly conducting GMP assessments and investigations, resolving warning letters and import alerts, and appearing in front of the FDA on behalf of companies to resolve enforcement actions.
Discounts and Additional Information:

Contracts info@liveoakqa.com for groups of five or larger and receive a 10% discount code for checkout
Tea Breaks and lunch are included in the workshop.

Sidley Healthcare Investment Conference 2024
2024-09-24 | The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, United Kingdom
Deal and investment activity remains critical to the success of life sciences and healthcare innovation.
RSVP Here

Sidley once again brings together senior pharma, biotech, healthcare, private equity, and venture capital executives to share their perspectives on critical issues, trends, and opportunities.
Join Sidley and industry leaders from across the globe, including from AstraZeneca, BioCentury, Compass Pathways, Financial Times, Flagship Pioneering, IQVIA, J.P. Morgan, LetterOne Health, Mestag Therapeutics, Morgan Stanley, Novartis, Onex, Permira, Perspectum, Rothschild & Co., Sofinnova Partners, Syncona, SV Health Investors, and Teva for this in-person, all-day event. Virtual attendance is available to those outside the UK.
View the agenda here.
View confirmed speakers here.
Panels will include:

Private Equity – What is the outlook for PE investment activity across Healthcare and Life Sciences? Which domains will be the “winners”?

Artificial Intelligence – To what extent, and where, does AI represent an investment opportunity across Healthcare and Life Sciences?

Fireside Chat – “A Life in Pharma and Pivoting to Innovation”- A conversation with Richard Francis, President and CEO, Teva.

A View From the Banks – Opinions, insights, and predictions on the market from a group of leading global healthcare dealmakers.

Pharma Business Development – Senior BD and biotech figures debate the M&A, licensing, and collaboration climate. Which therapeutic areas and geographies are garnering the most attention?

Venture/Growth Capital – How are global funds investing in a more muted market? How do investees stand out? Views from leading global life sciences investors.

Please note, due to space limitation for this event, registrations will be reviewed and confirmed by email in due course. We strongly encourage in-person attendance and remote participation will be available to those based outside of the UK.
For more information or questions, please contact lnevents@sidley.com.
SIDLEY HEALTHCARE INVESTMENT CONFERENCE 2023 HIGHLIGHTS

View the 2023 agenda
Sidley Healthcare Investment Conference 2023 Highlights Video
A Life Well Invented: A Discussion Between Moderna Co-Founder and Chairman Noubar Afeyan and Sidley’s Robert Darwin

Combination Therapies – EU Regulatory and Competition Law Headwinds and Strategies
2024-10-22 17:30 - 21:00 (Europe/Zurich) | Memox, Peter-Merian Strasse 80, Basel, 4052, Switzerland
Join us in Basel for our next Women’s Life Sciences Network event. The panel will discuss key considerations related to authority expectations as well as challenges, and potential strategies for EU regulatory and competition law compliance for combination therapies.

RSVP here.

Speakers are:

Dr. Sandra Zaugg Kunz, Head Regulatory Assessment Deputy Head of Medicinal Product Authorisation and Vigilance, Swissmedic
Elisabeth Leimbacher, Global Legal Lead, Marketing and Commercial Excellence, Takeda
Celine Fang, Senior Antitrust Counsel, Novartis

The discussion will be moderated by Josefine Sommer and Anne Robert, Partner, Sidley.
AGENDA
5:30 p.m. – Arrival and registration
6:00 p.m. – Panel discussion and Q&A
7:30 p.m. – Networking and apéro riche
For more information, please contact gvaevents@sidley.com.
Click here to join the Women’s Life Sciences Network LinkedIn Group.
For more information about previous editions, please click here.

Good Manufacturing Practice 2024Swiss/FDA Mutual Recognition Agreement – State of Play
2024-11-14 14:00 - 18:30 (Europe/Zurich) | Memox, Peter-Merian Strasse 80, Basel, 4052, Switzerland
Join us in Basel, where Sidley and thought leaders will be discussing the FDA and Swissmedic Mutual Recognition Agreement on Good Manufacturing Practices for pharmaceutical products. This agreement aims to streamline regulatory processes and enhance cooperation between the two countries by recognizing each other’s GMP inspections, thereby reducing the need for duplicative inspections.

RSVP here.
We will discuss early experiences with the new framework — both positive outcomes and challenges — highlighting valuable lessons learned and exploring potential for future developments.
Topics will include:

FDA/Swiss Mutual Recognition Agreement
AI and Good Manufacturing Practice
EU’s New Revised Annex 1

Featured speakers:

Christian Schärer, Head of Inspectorate, Swissmedic, (keynote speaker)
Oliver Schläfli, Senior Vice President Global Quality, Lonza
Jay Jariwala, Senior Director Regulatory Compliance, Sidley
James Johnson, Partner, Sidley
Eva von Mühlenen, Senior Advisor, Sidley

WHO SHOULD ATTEND?
Executives, in-house counsel, quality and compliance managers and officers interested in and/or facing GMP compliance and quality management challenges in Switzerland.
For more information or questions, please contact gvaevents@sidley.com.

Regulatory Know-How for Growth-Stage Life Sciences Innovators
2025-03-05 13:00 - 16:30 (America/Los_Angeles) | Torrey Heights, 11208 El Camino Real, San Diego, CA, 92130, United States
Please join Sidley’s Global Life Sciences team to lean into key early-stage and emerging growth regulatory issues, and how to tackle them.

If have questions or are interested in attending, please contact laevents@sidley.com.
Sessions will focus on:

All phases of clinical research and development
Press releases and disclosures
Regulatory wisdom from experienced emerging growth General Counsels

Connect with industry peers and investors during networking breaks and a post-program cocktail hour.
This program is designed for legal professionals and executives to provide a foundation in FDA, healthcare, and securities issues arising in development stage companies.
Featured Speakers

Himani Bhalla, Senior Managing Director, Chief Investment Officer, and Co-Founder, Symbiotic Capital
Greg Bowman, Senior Director, Leasing, Breakthrough Properties
Michael Brown, Executive Vice President and Chief, Legal Officer, DexCom, Inc.
Aneta Ferguson, Senior Vice President and General Counsel, Adverum Biotechnologies
Michael Mueller, General Counsel, Sidewinder Therapeutics, Inc.

Sidley Speakers

Torey Cope, Food, Drug, and Medical Device Regulatory
Meenakshi Datta, Healthcare: Drug and Medical Device Regulatory
Carlton Fleming, Capital Markets
Cindy Lovering, Global Finance
James Lu, Emerging Companies and Venture Capital
Jon Olsen, M&A, Emerging Companies and Venture Capital
Adam Welland, Technology and Life Sciences Transactions
Sharon Flanagan, M&A, Capital Markets, Corporate Governance

Agenda
1:00 p.m.: Registration
1:30 – 4:30 p.m.:

Clinical Research Challenges and Opportunities
Key Considerations for Press Releases and SEC Disclosures
Fireside Chat: The Importance of Regulatory Strategy and Compliance from Seasoned Emerging Growth GCs

4:30 – 6:30 p.m.: Cocktail Reception
CLE credit for this program is pending.

Boston Life Sciences Roundtable
2025-05-19 | The Institute of Contemporary Art/Boston, 25 Harbor Shore Drive, Boston, MA, 02210, United States
Join Sidley’s Life Sciences team for an afternoon of thought-provoking and engaging discussions touching on the latest trends and hot topics including the new administration, new technologies, the investment landscape, and more.

For more information, contact bosevents@sidley.com.

This year’s fifth annual event will be held in the stunning Institute of Contemporary Art/Boston lobby, followed by a reception on the picturesque harbor front plaza.
Please see below for details on our newly announced panels and panelists.
WHO SHOULD ATTEND
Executives, Investors, General Counsel, and Company Counsel
AGENDA
Registration: 1:30 p.m. ET
Program: 2:00 p.m. ET
Reception: 5:00 p.m. – 6:30 p.m. ET
FEATURED PANEL TOPICS
The New Administration, Trade Wars, and GC Strategies For Managing A Changing Environment
As the New Administration brings personnel and policy changes to HHS and FDA, and trade wars add new considerations for product development and manufacturing, we reflect on key developments and strategies GCs use to successfully manage the opportunities and risks in a changing environment.
– Lana Gladstein, General Counsel, Seaport Therapeutics
– Jose Truzman, General Counsel – U.S., Intercept Pharmaceuticals, Inc.
– Aaron Applebaum, Counsel, Global Arbitration, Trade and Advocacy
– Jackson Garvey, Partner, Restructuring & Liability Management
– Becky Wood, Partner, Global Co-leader, Food, Drug and Medical Device and Former Chief Counsel, FDA
New Product Development Pathways for Success
This panel will discuss key areas of focus during product development to set companies up for success, including the use of artificial intelligence (AI), pre-approval compliance considerations, and pricing strategies.
– Meena Datta, Partner, Global Co-leader, Healthcare
– Deeona Gaskin, Partner, Food, Drug and Medical Device and Former Associate Chief Counsel for Enforcement, FDA
Navigating Life Sciences Transactions in a Dynamic Economic Landscape
This panel will discuss the evolving landscape of life sciences transactions, including emerging trends in the current investment climate.
– Shaan Gandhi, Head of Strategic Partnerships, Pfizer Ignite
– Paresh Kumar, Vice President, Biotech Private Equity, Ally Bridge Group
– Jason Tse, Vice President Corporate Development, McKesson
– Chris York, Vice President, General Counsel & Chief of Staff, Orchard Therapeutics
– Mat Eapen, Partner, Investment Funds
KEYNOTE ADDRESS
“Get Your Mindset Right”: Thriving in Change
A Conversation with Kirk Taylor, MD on Navigating Changing Times
Kirk Taylor, MD
President & CEO
Massachusetts Life Sciences Center
Kirk Taylor, MD is a global pharmaceutical executive with expertise in Phase II – IV drug development, including CNS, oncology and rare disease. As Chief Medical Officer, Chief Strategy Officer and SVP Medical Affairs, he has restructured organizations, created strategic operating plans, and shaped corporate culture. His entrepreneurial acumen assisted in leading biotech start-up companies to successful IPOs and multiple funding rounds. He is people-first focused, leading teams with respect and innovation. In recognition of his positive impact, he was awarded the 2023 PharmaVoice 100 Executives Award.
Dr. Taylor received his Bachelor of Arts from Harvard College and studied piano at the Longy School of Music in Cambridge. He completed his Doctor of Medicine from the State University of New York, Downstate, his neurology residency at Einstein College of Medicine, and a post-doc at UCSF.

Women’s Life Sciences Network Event – Brussels
2025-05-20 17:30 - 20:00 (America/Chicago) | Comet, Place Stephanie 50, Brussels, 1050, Belgium
Join us in Brussels for our next Women’s Life Sciences Network event on the occasion of the EU Pharmaceutical Law Forum. The event will feature a moderated discussion on topical issues of pharmaceutical legislation and policy.

RSVP here.
SPEAKERS

Rainer Becker, Director, DG SANTE, European Commission
Victoria Kitcatt, Vice President and Assistant General Counsel, Head of EU/International Regulatory Law, Pfizer
Laetitia Szaller, General Counsel, Head of Compliance and ESG, Egetis Therapeutics

A Q&A session will follow the discussion.
AGENDA
5:30 p.m. – Welcome
6:00 p.m. – Panel discussion
7:00 p.m. – Networking reception and canapés
All are invited to attend WLSN events.

Good Manufacturing Practice 2025AI in Manufacturing
2025-06-03 15:45 - 17:00 (Europe/Zurich)
Join us for an insightful and practical webinar on “Navigating AI Adoption in GMP-Regulated Areas While Staying Compliant.”

Webinar | RSVP here.
Key Insights:

AI in Pharma Production: Explore how AI is revolutionizing pharmaceutical production through process automation, real-time quality control, predictive maintenance, and AI-driven batch release decisions.
Regulatory Perspectives: Gain insights into how regulators in the U.S. and the EU are approaching AI in GMP-compliant manufacturing, focusing on validation, risk management, and compliance expectations.
Broader Frameworks: Understand how AI adoption fits into broader regulatory frameworks like the EU AI Act.

Featured Speakers:

Gert Thurau, Lead Technology Innovation Manufacturing, CMC Regulatory Policy, Roche
James Johnson, Partner, Sidley
Daniel J. Roberts, Senior Director, Regulatory Compliance, Sidley
Eva von Mühlenen, Senior Advisor, Sidley

Why Attend?
This session will provide a real-world discussion on how companies can effectively integrate AI into their operations while adhering to Good Manufacturing Practice (GMP) regulations.
Learn from industry and regulatory thought leaders about the latest trends and best practices in AI adoption within GMP-regulated environments.
Who Should Attend?
Executives, in-house counsel, quality and compliance managers and officers interested in and/or facing GMP compliance and quality management challenges in Switzerland.

For more information or questions, please contact gvaevents@sidley.com.
Nothing in this program may be quoted or used in any manner without the express written consent of Sidley Austin LLP. The views expressed in this program are the views of the participants, and not necessarily those of the firm. This program is for informational purposes only and should not be considered legal advice or creating an attorney-client relationship.

Bay Area Lifesciences Roundtable Navigating Uncertainty and Charting a New Course
2025-07-23 13:00 - 16:30 (America/Chicago) | SFMOMA, 147 Minna St. Floor 5, San Francisco, CA, 94103, United States
Join industry leaders, investors, and seasoned regulatory counsel for an exclusive event focused on thriving during times of change in the life sciences sector. Through dynamic panel discussions, we’ll explore the latest trends in regulation, financing, market dynamics, and federal health policy, all with a focus on how companies can continue to realize the transformative impact of new therapies and technologies. Don’t miss this opportunity to connect, learn, and chart a new course for long-term business success.
RSVP here.
AGENDA
Registration | 1:00 p.m.
Program | 1:30 p.m.
Reception 4:30 p.m.
Who may be interested in attending: Executives, Directors, Investors, and In-House Counsel
FEATURED PANELS
Regulatory Realities – Proactive Strategies in a Shifting Landscape
Explore how companies are developing new strategies to respond to the latest developments at HHS, FDA, and CMS, including major shifts in FDA leadership, staffing, and policy priorities, potential impacts on regulatory timelines and new product approvals, and new proposals related to drug pricing and reimbursement. Hear from industry insiders on how to engage effectively with regulators and adapt to new expectations in an era of uncertainty.
SPEAKERS

Anthony Davies, Ph.D., Founder & CEO, Dark Horse Consulting
Hae-Won Min Liao, Vice President, U.S. Legal Business Partner, Gilead Sciences
Emily Marden, Senior Counsel, Sidley
Catherine Starks, Partner, Sidley

Additional panelists to be announced
Financing the Future – Paths to Growth and Liquidity
Discover how investment opportunities are evolving, with a focus on financing and liquidity options including debt, royalty financing, mergers, and other strategic transactions. Leading advisors and investors will share their experience, including how shifting geopolitical and regulatory factors are shaping deals, and what it takes to secure funding and achieve liquidity in today’s market.
SPEAKERS

Ryuk Byun, Managing Director, Morgan Stanley
Hutch Corbett, Managing Partner, Armentum Partners
Carlton Fleming, Partner, Sidley
Frank Rahmani, Partner, Sidley

Additional panelists to be announced
The GLP-1 Effect – Disruption, Demand, and What’s Next for Biotech
Using GLP-1 as a case study, dive into the latest trends in product development, pricing and reimbursement, market dynamics, and federal health policy. This panel will examine issues that have arisen for the paradigm-shifting GLP-1/GIP/Gcg product category, to reveal for the future of innovation across the entire life sciences industry.
SPEAKERS

Scott Akamine, Chief Legal Officer, Kailera Therapeutics
Michael Hulka, Senior Vice President and Deputy General Counsel, Eli Lilly and Company
Torrey Cope, Partner, Sidley

Additional panelists to be announced
CLE credit for this program is pending.

For more information, contact sfevents@sidley.com.

Swiss MedTech 2025Staying Competitive in a Shifting Regulatory Landscape
2025-09-02 14:00 - 18:30 (Europe/Zurich) | Casino Bern, Casinoplatz 1, 3011, Bern, Switzerland
The Swiss MedTech industry stands at a critical crossroads: navigating rapid regulatory evolution, geopolitical shifts, and emerging technologies.

RSVP here.
For more information, please contact Geneva Events.

Join us in Bern for an interactive afternoon featuring regulators, industry leaders, legal professionals, and scientific advisors who will share practical insights, best practices, and strategic foresight.
Key highlights on the agenda include:

Regulatory Realities and Priorities
How Swiss MedTech Stays Competitive Amid Regulatory Shifts
Global Trade and Politics
U.S. Policy in 2025 – Implications for Swiss Market Access and Trade Strategy
Corporate Responsibility
From ESG to the Omnibus Act – What Swiss MedTech Must Now Comply With
New Pathway of Regulating Artificial Intelligence in Switzerland
Competitive Edge or Compliance Hurdle?

Singapore Life Sciences Roundtable
2025-09-03 09:30 - 13:00 (Asia/Singapore) | Sidley, 1501 K Street, NW Washington, D.C., 20005, United States
This intimate, industry-focused session will bring together legal and compliance professionals from multinational pharmaceutical, medtech, and biotech companies to explore how recent global developments are reshaping the regulatory and transactional landscape across Asia-Pacific.

RSVP here.

Topics include:
– The New DOJ White Collar Enforcement Playbook
What it means for APAC operations and compliance functions
– The New U.S. Administration and the FDA
Taking stock of paradigm-shifting developments in drug and device regulation
– Life Sciences Transactions in APAC
Navigating deal risks, regulatory scrutiny, and cross-border trends
PROGRAM
Registration and Refreshments: 9:30 a.m. – 10:00 a.m. SGT
Sidley Presentation and Roundtable Dialogue: 10:00 a.m. – 12:00 p.m. SGT
Networking Lunch: 12:00 p.m. – 1:00 p.m. SGT
For questions or more information, please contact asiaevents@sidley.com.

Sidley’s Medicaid Drug Rebate Program Summit Cocktail Reception
2025-09-15 18:00 - 20:00 (America/Chicago) | Avli on the Park, 180 N Field Blvd, Chicago, IL, 60601
Please join members of Sidley’s Drug Pricing Team for appetizers and cocktails – right near Chicago’s iconic Bean in Millennium Park – following Day 1 of the MDRP Summit.

RSVP here

We look forward to connecting with you!
For questions, please contact chevents@sidley.com.

Sidley Healthcare Investment Conference 2025
2025-09-30 | The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, United Kingdom
With deal and investment activity remaining critical to the success of the life sciences and healthcare industry, Sidley is bringing together senior pharma, biotech, healthcare, private equity, and venture capital leads to provide their insights on key topics, trends, and opportunities.

RSVP here.

Join Sidley and industry leaders from across the globe for this in-person, one-day event in London, with the option to stream and network virtually from outside the UK.
We look forward to incisive content, robust discussion, and valuable networking during a day of looking at the continued combination of innovation and capital driving positive patient outcomes and investment returns.
View the Sidley Healthcare Investment Conference 2024 highlights.

Women's Life Sciences NetworkGeopolitical and Trade Uncertainties: Strategies for the Life Sciences Industry
2025-10-21 17:30 - 21:00 (Europe/Zurich) | Memox, Peter-Merian Strasse 80, Basel, 4052, Switzerland
Join us in Basel for our next Women’s Life Sciences Network event, which will feature a panel discussion with leading life science industry representatives about the challenges and opportunities arising from increasingly volatile and fragmented international trade dynamics.

RSVP here.
The panel will share insights and considerations on the impact on life science companies’ operations and compliance efforts of, among others, new tariffs, retaliation measures, and other recent trade restrictions implemented in an evolving geopolitical context where countries seek to rebalance trade relations. A Q&A session will follow the moderated discussion.

All are invited to attend WLSN events.
AGENDA
5:30 p.m. – Arrival and registration
6:00 p.m. – Panel discussion and Q&A
7:30 p.m. – Networking and apéro riche
For more information, please contact brevents@sidley.com.

Biotech Dealmaking - Regulatory Considerations for the Next Wave of Development-Stage Transactions - Program and Lunch
2026-01-12 11:30 - 14:30 (America/Los_Angeles)
Join members of Sidley’s Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.

Led by Meena Datta, global co-leader of Sidley’s Healthcare practice; Torrey Cope, partner in Sidley’s Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley’s M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.
For questions, please contact sfevents@sidley.com.

Connecting Clusters of Excellence: Europe as Your Gateway to Global Success
2026-01-12 13:30 - 17:30 (America/Los_Angeles) | The Town Hall, 555 California Street, San Francisco, CA, 94104, United States
Join Sidley, Biovia, Health Campus Limburg DC, and others for an engaging afternoon exploring collaborative growth opportunities across the global life sciences landscape.

RSVP here.
The event will feature two dynamic panel discussions, with the latter being moderated by Sidley’s Becky Wood, global co-leader of Sidley’s FDA practice and former Chief Counsel at FDA.
Panel 1: Europe Recharged: Innovation Thrives Here. We Are Ready for the Global Stage.
Europe’s biotech and healthtech ecosystems are accelerating. With strong public-private partnerships, world-class research, and coordinated investment strategies, Europe is no longer catching up, it’s setting the pace. Discover how clusters across the continent are shaping global markets through collaboration and scale.
Panel 2: Redefining Women’s Health: Europe and the U.S. Unite to Power Innovation, Investment, and Impact.
A new wave of investors and innovators is turning women’s health into one of the fastest-growing markets in healthcare. How can we ensure women’s health is not just a “hot topic,” but an enduring pillar of innovation and research? This panel brings together U.S. and European leaders driving science, technology, and capital toward an overdue revolution in women’s health, from overlooked needs to global opportunities.
This gathering brings together leaders, innovators, and ecosystem builders to spark meaningful dialogue and foster new pathways for international collaboration.
Please note that delegate contact details may be passed between Sidley Austin LLP, Biovia, and Health Campus Limburg DC for the purposes of organizing and administering these events, and for contacting you about these events. The organizers are using third party websites, not controlled by Sidley, and your personal information will be processed in accordance with the Eventbrite Privacy Policy. For information on Sidley’s use of your personal information please refer to our Privacy Policy and for questions about these events please contact sfevents@sidley.com.

At the Table: Serving Up a Lively Discussion With the FDA and USDA
2026-01-28 09:30 - 16:30 (America/New_York) | Sidley, 1501 K Street, NW Washington, D.C., 20005, United States
Please join Sidley’s Food, Drug, and Medical Device team for a Meet the Regulators Roundtable which will include: Stephen A. Vaden, USDA Deputy Secretary; Tyler Clarkson, USDA General Counsel; Kyle Diamantas, FDA Deputy Commissioner for Human Foods, and Sean Keveney, FDA Chief Counsel.

For registration information, please contact dcevents@sidley.com.

Agenda
Registration | 9:30 a.m. ET
Panels | 10:00 a.m. – 12:10 p.m. ET
Lunch | 12:15 p.m. – 1:15 p.m. ET
Meet the Regulators Roundtable | 1:30 p.m. – 3:00 p.m. ET
Cocktail Reception | 3:00 p.m. – 4:30 p.m. ET
The event will bring together industry leaders for a lively discussion on regulatory compliance, enforcement actions, litigation, and related issues facing the food industry.
Panel discussions prior to the Regulator Roundtable will include:
– The Changing Landscape in Washington Food Regulation
– Enforcement and Litigation – Risks, Opportunities, and Trends
CLE credit is pending for this program. Sidley Austin LLP is an Approved Accredited Provider of CA, IL, and NY CLE credit.

Life Sciences College 2026
2026-02-12 08:30 - 17:00 (Europe/Brussels) | Renaissance Brussels Hotel, Rue du Parnasse 19, Brussels, 1000, Belgium
Join EUCOPE and Sidley for the annual Life Sciences College (LSC) for an exclusive, full-day forum on the future of life sciences in Europe.

RSVP here.
Get ready for a high-impact day of insight and connection at LSC, where life sciences leaders gather to explore the legal, regulatory, and policy shifts shaping the industry.
Why Attend?

– Connect with key decision-makers from the European Commission, regulatory bodies, industry, and the investment community
– Hear exclusive insights on legal, policy, and regulatory trends shaping the EU life sciences landscape
– Join strategic discussions on emerging challenges and opportunities across the sector
– Network with leaders from pharma, biotech, medtech, and venture capital
Who Should Attend
In-house counsel, regulators, and regulatory personnel.There is no registration fee to attend this event.
For more information, contact brevents@sidley.com.

Sidley Sponsors the 2026 EU Pharma Law Forum
2026-05-19 - 2026-05-21 | Steigenberger Icon Wiltcher’s, Brussels
Sidley is proud to sponsor and participate in the EU Pharma Law Forum, the leading annual gathering of regulators, in-house counsel, policymakers, and industry stakeholders shaping the future of European pharmaceutical law.
View agenda here.
Sidley partner Anne Robert will be speaking on “How to Respond to Dawn Raids and Investigations.” Josefine Sommer will present on “Early Experiences from the HTA Regulation: Market Access Pricing and Reimbursement.”
We look forward to connecting with clients, colleagues, and industry leaders in Brussels to discuss the evolving legal landscape and the strategic considerations facing the pharmaceutical sector in 2026 and beyond.

Women’s Life Sciences Network – Biotech Act: Funding and Investment Opportunities
2026-05-19 17:30 - 21:00 (Europe/Brussels) | Comet, Place Stephanie 50, Brussels, 1050, Belgium
Join us in Brussels for our next Women’s Life Sciences Network event on the occasion of the EU Pharmaceutical Law Forum.

RSVP here.

Our speakers will discuss the proposed Biotech Act I, focusing on funding and regulatory support opportunities for the European biopharmaceutical industry.
Join our moderated panel discussion with:
Felicitas Riedl, Director of Innovation and Competitiveness Department, European Investment Bank
Alexandra Eftimie, Legal and Policy Officer, European Commission
Kristin Thompson, Director, Merieux Equity Partner
Valerie Vanhooren, CEO & Co-founder, Ona Therapeutics
The event will include a video address by Stine Bosse, MEP for the Renew Europe group and Vice Chair of the Committee on Public Health in the European Parliament.
Agenda
Welcome and registration – 5:30 p.m. CEST
Panel discussion and Q&A – 6:00 p.m. CEST
Networking reception and canapés – 7:30 p.m. CEST
Stay tuned for more details. All are invited to attend WLSN events.
